...hired Susan Rodriguez as chief commercial officer, a newly created role. She was CEO of Tolmar...

...for Gene Therapy” ). Approval for Tolmar’s early puberty therapy FDA approved an NDA for Tolmar...
...Vascular endothelial growth factor A BioCentury Staff vadadustat (MT-6548, akb-6548) ADVM-022 (AAV.7m8-aflibercept) ublituximab (TG-1101, TGTX-1101, LFB-R603) umbralisib (TGR-1202, rp5264) SRI International Exscientia Ltd. Tolmar Inc. Akebia...

...B) Gammagard Liquid immune globulin Autoimmune $212.0 Eli Lilly Erbitux cetuximab Cancer $211.8 AbbVie / Tolmar...

...to receive $105 million in contingent payments tied to prostate cancer treatment Eligard leuprolide from Tolmar Inc....

...subsequently acquired by QLT Inc. (TSX:QLT; NASDAQ:QLTI, Vancouver, B.C.). In 2009, QLT divested Eligard to Tolmar Inc....

...Diagnostic Hired: David Barshis, a director, as CEO; formerly COO of Zila Inc. , which Tolmar Inc....

...the former COO of dental and diagnostic company Zila Inc. , which was acquired by Tolmar Inc....

...divested Eligard to Tolmar (see BioCentury, July 26, 2010). Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Tolmar Inc....

...2009, QLT divested Eligard to Tolmar Inc. (Fort Collins, Colo.). The deal terminates MediGene's obligations to Tolmar...

...land. Figures do not include prostate cancer drug Eligard leuprolide acetate, which QLT divested to Tolmar Inc....